Independent data review supports continuation of phase III programme with intravenous iclaprim
The results are blinded to Arpida and will remain so until the trial is fully completed. The global Phase III ASSIST trials are designed to compare the efficacy and safety of iclaprim with that of market leader linezolid (marketed by Pfizer as Zyvox®). Both ASSIST-1 and ASSIST-2 are global, multicenter trials conducted in various countries in North America, Europe and the rest of the world. Arpida expects to complete ASSIST-1 before the end of 2006.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.